TrialPath
★ Lung cancer

Lung cancer clinical trials — recruiting now

There are 20+ lung cancer studies currently recruiting participants across the US. Every eligibility criterion translated into plain English.

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years
WherePhiladelphia, Pennsylvania, United States
SponsorAbramson Cancer Center at Penn Medicine
▾Tap for details
Apply

Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC

NCT07398937 · Resectable Stage II-IIIa Squamous NSCLC
Recruiting

This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined with chemotherapy in neoadjuvant therapy. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1036.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereShanghai, Shanghai Municipality, China
SponsorFudan University
▾Tap for details

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Recruiting

This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy in subjects with resectable stage IIIA and IIIB (N2) NSCLC. Primary study endpoints are MPR rate assessed by BIPR and EFS assessed by BIRC.

PhasePhase 3
TypeInterventional
Age18 Years
WhereTianjin, Tianjin Municipality, China
Sponsor3D Medicines (Sichuan) Co., Ltd.
▾Tap for details
Apply

Tier Palliative Care For Patients With Advanced Heart Failure or Cancer

NCT07391956 · Advanced Heart Failure, Advanced Non-Colorectal Gastrointestinal Cancer, Advanced Lung Cancer
Recruiting

TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines. In Tier 1, patients who are able to care for themselves and no/mild symptoms receive a community health worker (CHW) trained to elicit illness understanding in a culturally competent way. In Tier 2, for patients with poorer function and mild symptoms, a social worker (SW), trained in serious illness communication, joins the CHW to further elicit patients' goals and prognostic understanding while communicating symptom needs to their primary clinician. In Tier 3, as function decreases and symptoms increase, an advance practice nurse (APN) joins the CHW and SW to manage complex symptoms. Finally, in Tier 4, for those older adults with the poorest function and most complex symptoms, a physician joins the team to ensure that the most complex needs (e.g., end-of-life treatment preferences and multifaceted symptom control) are met. The CHW follows patients longitudinally across all tiers and re-allocates them to the appropriate tier based on their evolving needs.

PhaseNA
TypeInterventional
Age18 Years
WhereAstoria, New York, United States + 4 more
SponsorIcahn School of Medicine at Mount Sinai
▾Tap for details
Apply

Development of Clinical and Biological Database on Bronchial Cancer

NCT07085429 · Lung Cancer, Bronchial Cancer
Recruiting

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.

PhaseNA
TypeInterventional
Age18 Years
WhereMontpellier, France, France
SponsorInstitut du Cancer de Montpellier - Val d'Aurelle
▾Tap for details
Apply

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939 · Non-Small Cell Lung Cancer, c-MET
Recruiting

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

PhasePhase 2
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 82 more
SponsorAbbVie
▾Tap for details
Apply

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

NCT06228066 · Small Cell Carcinoma of the Bladder, High Grade Neuroendocrine Tumors of the Urinary Tract
Recruiting

Background: Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET. Objective: To test lurbinectedin with or without avelumab in people with SCCB or HGNET. Eligibility: Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment. Design: Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor. Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects. Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function. Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.

PhasePhase 2
TypeInterventional
Age18 Years – 120 Years
WhereBethesda, Maryland, United States
SponsorNational Cancer Institute (NCI)
▾Tap for details
Apply

Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression

Recruiting

This is a single-arm, exploratory phase Ib/II study with a seamless design to evaluate the safety and efficacy of Vebreltinib combined with furmonertinib as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR-sensitive mutations (exon 19 deletion or L858R) and PD-L1 TPS ≥50%. In the phase Ib part, 12-16 patients will be enrolled to compare the safety and early efficacy of Vebreltinib 100mg BID versus 150mg BID in combination with furmonertinib 80mg QD, and to determine the recommended phase II dose (RP2D). In the phase II part, 37 patients (including evaluable patients from the RP2D cohort in phase Ib) will receive treatment at the RP2D. The primary endpoint is investigator-assessed median progression-free survival (PFS). Secondary endpoints include objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Exploratory endpoints will analyze the correlation between baseline MET abnormalities and treatment efficacy.

PhasePhase 1 / Phase 2
TypeInterventional
Age18 Years – 75 Years
WhereNanchang, Jianxi, China
SponsorSecond Affiliated Hospital of Nanchang University
▾Tap for details
Apply

PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC

NCT07645222 · Lung Cancer
Recruiting

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-20122 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereGuangzhou, Guangdong, China
SponsorHansoh BioMedical R&D Company
▾Tap for details

Enhanced COPD Management in Suspected Lung Cancer Patients

Recruiting

Identifying and treating COPD in patients undergoing lung cancer evaluation is crucial. Early intervention could lead to better management of both diseases, improving health status, reducing healthcare costs, and potentially increasing survival rates. This study aims to assess the impact of early diagnosis and optimal treatment of COPD on clinical outcomes in patients under evaluation for lung cancer. The study will combine information through an open-label RCT at the Lung Cancer Investigation Unit at Lillebaelt Hospital Vejle. The findings could inform clinical practice by emphasizing the importance of integrated care approaches for patients with coexisting COPD and lung cancer, ultimately leading to better health outcomes.

PhaseNA
TypeInterventional
Age18 Years
WhereVejle, Denmark
SponsorDitte Krag-Hansen
▾Tap for details
Apply

Decoding the Association of Imaging and Tumor Microenvironment in Lung Cancer Using Radiogenomic Approach(Radiogenomics-Lung)

NCT06500312 · Lung Cancer
Recruiting

This is the prospective, observational cohort study (Radiogenomics-Lung), which aims to explore the relationship between the imaging information of lung cancer patients, tumor microenvironment and the prognosis of lung cancer patients.

Phase—
TypeObservational
Age18 Years
WhereWuhan, Hubei, China
SponsorUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
▾Tap for details
Apply

68Ga-SorB PET/CT Imaging in Patients With Solid Tumors

NCT07760012 · Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer
Recruiting

This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors. Eligible participants with confirmed or suspected melanoma, hepatocellular carcinoma, lung cancer, pancreatic cancer, breast cancer, ovarian cancer, or cholangiocarcinoma will undergo 68Ga-SorB PET/CT imaging. The imaging findings will be compared with standard-of-care 18F-FDG PET/CT, using pathology results and/or clinical follow-up as the reference standard. The primary objectives are to evaluate the safety and tolerability of 68Ga-SorB, assess imaging feasibility, and characterize tumor uptake using quantitative PET parameters, including SUVmax and tumor-to-background ratio (TBR). Secondary exploratory objectives include comparing lesion detection between 68Ga-SorB PET/CT and 18F-FDG PET/CT, assessing diagnostic sensitivity and specificity, evaluating imaging characteristics across different tumor types, and exploring the correlation between Sortilin expression and tracer uptake. This study will provide preliminary clinical evidence supporting the development of Sortilin-targeted molecular imaging and future theranostic applications.

PhaseNA
TypeInterventional
Age18 Years
WhereBeijing, Beijing Municipality, China
SponsorPeking University Third Hospital
▾Tap for details
Apply

Long-Terms Responders in Metastatic Lung Cancer: Better Understanding for Better Management (Lungevity Study)

Recruiting

The goal of this observational study is to identify and describe the clinical characteristics, health status, socio-economic impacts and quality of life of patients alive for three years after diagnosis of metastatic Lung cancer and no longer receiving cytotoxic chemotherapy. The main question is to identify the needs of these patients in terms of health status (impact of cancer treatments, incidence of new diseases, cardiovascular, diabetes, second cancers), socio-economic aspects, quality of life and return to employment. Participants will be asked to answer quality of life questionnaires at the time of inclusion and 6 and 12 months after inclusion and then, every year up to 5 years in this study. They will be followed regularly, in consultations, according to the usual practices of the physicians in each participating center.

Phase—
TypeObservational
Age18 Years
WhereAix-en-Provence, France + 45 more
SponsorGFPC Investigation
▾Tap for details
Apply

Study of Collection and Analysis of Clinical, Anamnestic, Functional, Biological Data Through the Support of Artificial Intelligence to Evaluate the Possibility of Defining a Digital Twin of the Lung (LUCE)

NCT07517393 · Thoracic Neoplasm, Pulmonary Nodules, Non-oncological Pulmonary Pathologies
Recruiting

This research study aims to retrospectively and prospectively analyze the clinical, anamnestic, functional, biological data of patients who have performed or will perform non-contrast chest photon count CT. The use of contrast medium is evaluated by the physician. Main objective The study aims to understand how many people who undergo non-contrast photon-counting chest CT have: lung nodules, chest tumors, and other non-cancerous lung diseases. Secondary objectives * Analyze the data with the help of artificial intelligence to create a "digital twin" of the lung, that is, a virtual copy of the lung that allows you to study and simulate the behavior of the lung for research and analysis purposes, without directly intervening on the patient. * Follow any suspicious lung changes over time to understand how they change and whether they are linked to clinical, biological, or laboratory parameters. The enrollment phase will last 12 months and will begin with the approval of the study. At this stage, clinical data already present in the patient's medical record and data relating to the photon count CT examination will be collected. After the enrollment phase, the patient will be observed for a further total duration of 10 years: in particular, a follow-up visit will be arranged at two, five and ten years. More specifically, if there are no radiological elements that require scheduling a visit to the center, the patient will be contacted by telephone for a telematic update of the data. If, however, pulmonary alterations are identified during the study, the patient will be referred to the Reference Operating Unit, as per clinical practice, to continue with the most appropriate personalized diagnostic-therapeutic process. In these cases, the patient will be contacted by telephone and an appointment with the institution will be suggested.

Phase—
TypeObservational
Age18 Years
WherePeschiera del Garda, Verona, Italy
SponsorCasa di Cura Dott. Pederzoli
▾Tap for details

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Recruiting

This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

PhasePhase 2
TypeInterventional
Age18 Years
WhereChico, California, United States + 3 more
SponsorUniversity of California, Davis
▾Tap for details
Apply

MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

NCT04762199 · Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Recruiting

This phase Ib trial evaluates the best dose and side effects of MRX-2843 when given in combination with osimertinib in treating patients with EGFR gene mutant non-small cell lung cancer that has spread to other places in the body (advanced). MRX-2843 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PhasePhase 1
TypeInterventional
Age18 Years
WhereAtlanta, Georgia, United States
SponsorEmory University
▾Tap for details
Apply

Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

Recruiting

This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire technology. The study plans to enroll 40 treatment-naive patients with ES-SCLC.

Phase—
TypeObservational
Age18 Years
WhereZhengzhou, Henan, China
SponsorHenan Cancer Hospital
▾Tap for details
Apply

Is There a Benefit From Addition of Physical Exercise to Diet Restriction/Limitation in PCOS Women With Asthma?

NCT07446985 · Polycystic Ovary Syndrome, Asthma
Recruiting

Women with polysyctic ovarian syndrome (PCOS) usually develop many complications including asthma. Nowdays, diet restriction combimed with phsyical exercises may improve both problems

PhaseNA
TypeInterventional
Age20 Years – 30 Years
WhereGiza, Dokki, Egypt
SponsorCairo University
▾Tap for details
Apply

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

NCT06057935 · Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma
Recruiting

The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.

PhasePhase 2
TypeInterventional
Age18 Years
WhereChicago, Illinois, United States + 12 more
SponsorMemorial Sloan Kettering Cancer Center
▾Tap for details
Apply

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Recruiting

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnchorage, Alaska, United States + 289 more
SponsorAstraZeneca
▾Tap for details
Apply